Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Protocol: Pembrolizumab for early triple-negative breast cancer - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Pembrolizumab for early triple-negative breast cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Pembrolizumab for early triple-negative breast cancer

New Protocol: Pembrolizumab for early triple-negative breast cancer
Study:
  • Placebo controlled, randomized Phase III trial (KEYNOTE-522)
  • Newly diagnosed, non-metastatic (T1cN1-2 or T2-4N0-2), triple-negative breast cancer
  • CARBOplatin-PACLitaxel x 4 => AC/EC x 4 => Surgery => adjuvant Rx: With (n=784) or without (n=390) neoadjuvant and adjuvant pembrolizumab 200 q21. Adjuvant capecitabine not allowed
Efficacy:
  • Pathological CR: 64.8% vs. 51.2% (p < 0.001)
  • PFS @ 18 mos: 91.3% vs. 85.3% (HR: 0.63 [0.43-0.93])
Safety:
  • Any grade >= 3 AEs during neoadjuvant Rx: 81.0% vs. 75.8%

N Engl J Med 2020; 382:810-821

Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer

https://doi.org/10.1056/NEJMoa1910549

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More